Physician profile
Richard E Gordon
NPI 1730106352
$2,498.39
in general payments reported to CMS, 2019-2025
11 companies · $168 in 2025
The $168 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.96 · 2020: $709 · 2021: $959 · 2022: $271 · 2023: $96.36 · 2024: $223 · 2025: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $486.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,260.50 | 2020-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $509.68 | 2020-2022 | |
| Allergan, INC. | $229.66 | 2019-2020 | |
| Pfizer INC. | $193.80 | 2019-2024 | |
| Novo Nordisk INC | $112.66 | 2020-2025 | |
| Actelion Pharmaceuticals US, INC. | $74.99 | 2022 | |
| Sight Sciences, INC. | $35.74 | 2024 | Omni Surgical System |
| Array Biopharma INC | $31.87 | 2022-2023 | Mektovi, Lorbrena, Braftovi |
| Genzyme Corporation | $23.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.40 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Gordon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.